Incyte INCY Net sales — Total revenues

Other product segments

Similar metrics at other companies

ARDXProduct sales, net — Total revenues

$93.37M+37.7%

ESP

ESPRProduct sales, net — Total Revenues

$43.4M+24.3%

BCRXProduct sales, net — Total revenues

$151.4M+5.3%

TARSProduct sales, net — Total revenues

$145.39M+85.6%

SUPNNet product sales — Total revenues

$150.75M+6.2%

CRMDProduct sales, net — Total Revenue

$121.92M+212%

Questions, answered.

What is Incyte's net sales — total revenues?

Incyte (INCY) reported net sales — total revenues of $1.49B in Q2 2026.

How has Incyte's net sales — total revenues changed year-over-year?

Incyte's net sales — total revenues increased by 40.5% year-over-year, from $1.06B to $1.49B.

What is the long-term trend for Incyte's net sales — total revenues?

Over 4 years (2021 to 2025), Incyte's net sales — total revenues has grown at a 17.0% compound annual growth rate (CAGR), from $2.32B to $4.35B.

What does net sales — total revenues mean?

This metric represents the total gross revenue generated from the sale of pharmaceutical products after accounting for returns, allowances, and rebates. It serves as the primary indicator of market demand and commercial success for the company's portfolio of oncology and dermatology therapies. By isolating product-specific sales, it allows investors to evaluate the revenue contribution of key assets like Jakafi and other licensed treatments.